<DOC>
	<DOCNO>NCT00920816</DOCNO>
	<brief_summary>The study design demonstrate axitinib ( AG-013736 ) superior sorafenib delay tumor progression patient metastatic renal cell cancer .</brief_summary>
	<brief_title>Axitinib ( AG-013736 ) For Treatment Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically document metastatic renal cell cancer component clear cell histology . Evidence measurable disease . Patients mRCC must receive prior systemic firstline therapy must progressive disease per RECIST ( version 1.0 ) one prior systemic first line regimen metastatic disease contain sunitinib , cytokine ( ) , . Prior treatment metastatic renal cell cancer one systemic first line therapy . Major surgery le 4 week radiation le 2 week start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Axitinib First &amp; Second Line Treatment Patients With Metastatic Renal Cell Cancer</keyword>
</DOC>